Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 15,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, July 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00.
• On Monday, June 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00.

Gilead Sciences Price Performance

GILD opened at $135.25 on Wednesday. The firm has a market capitalization of $167.92 billion, a PE ratio of 18.43 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The business’s 50-day moving average is $129.58 and its two-hundred day moving average is $136.11.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.26) by $0.51. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.01 earnings per share. Research analysts anticipate that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Aviva PLC grew its position in shares of Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd purchased a new position in Gilead Sciences in the 4th quarter valued at about $1,418,000. NBC Securities Inc. lifted its stake in Gilead Sciences by 150.3% in the 4th quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock valued at $2,105,000 after buying an additional 10,296 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Gilead Sciences by 43.9% in the 4th quarter. Farther Finance Advisors LLC now owns 56,812 shares of the biopharmaceutical company’s stock worth $6,973,000 after buying an additional 17,325 shares during the last quarter. Finally, Flputnam Investment Management Co. increased its stake in Gilead Sciences by 66.5% during the 4th quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock worth $12,978,000 after buying an additional 42,243 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported a second-quarter loss of $6.75 per share, narrower than analyst estimates for a loss of roughly $7.07–$7.26. Revenue increased 10.6% year over year, while product sales rose 8% and exceeded Wall Street expectations. Gilead Sciences Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: HIV medicines generated double-digit sales growth, reinforcing the HIV franchise as Gilead’s main growth engine. Yeztugo, the company’s HIV pre-exposure prophylaxis drug, narrowly beat sales expectations and could provide additional longer-term growth. Gilead’s High-Profile HIV Drug Beat
• Positive Sentiment: Gilead prevailed in a California Supreme Court case concerning whether drugmakers have a duty to develop potentially safer alternatives to existing safe medicines. The ruling reduces a potential product-liability risk for the company. California Court Rules for Gilead
• Neutral Sentiment: Management’s fiscal 2026 EPS guidance of a $0.65–$0.30 loss is better than the consensus estimate for a $0.79 loss, but revenue guidance of $30.1 billion–$30.4 billion is slightly below the $30.5 billion analyst forecast. The outlook reflects the impact of acquisition-related costs and research-and-development spending.
• Negative Sentiment: Gilead lowered its full-year Veklury outlook after sales of the COVID-19 treatment plunged 81% in the quarter, highlighting continued pressure on a declining product. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: The quarterly loss compares with $2.01 in earnings per share a year earlier, with acquisition and R&D costs weighing heavily on profitability. Gilead Second-Quarter Sales Rise
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 trading plan. Because the sale was planned and he retained more than 592,000 shares, it is a limited negative signal but may attract investor attention.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on GILD shares. Truist Financial cut their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Citigroup lifted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wall Street Zen downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gilead Sciences in a report on Wednesday, July 29th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $157.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.